These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34787092)

  • 1. Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation.
    Sezgin O; Boztepe B; Üçbilek E; Altintas E; Celikcan HD
    Turk J Gastroenterol; 2021 Oct; 32(10):870-878. PubMed ID: 34787092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression.
    Perera LP; Radigan M; Guilday C; Banerjee I; Eastwood D; Babygirija R; Massey BT
    Dig Dis Sci; 2019 Jul; 64(7):1923-1928. PubMed ID: 30725303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irritable Bowel Syndrome-Like Symptoms in Ulcerative Colitis Patients in Clinical Remission: Association with Residual Colonic Inflammation.
    Ishihara S; Kawashima K; Fukuba N; Tada Y; Kotani S; Mishima Y; Oshima N; Kinoshita Y
    Digestion; 2019; 99(1):46-51. PubMed ID: 30554229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.
    Lundgren D; Rutegård J; Eklöf V; Palmqvist R; Karling P
    BMC Gastroenterol; 2016 Nov; 16(1):139. PubMed ID: 27881072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study.
    Fukuba N; Ishihara S; Tada Y; Oshima N; Moriyama I; Yuki T; Kawashima K; Kushiyama Y; Fujishiro H; Kinoshita Y
    Scand J Gastroenterol; 2014 Jun; 49(6):674-80. PubMed ID: 24646420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
    Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
    Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative characteristics of fatigue in irritable bowel syndrome and inflammatory bowel disease: A systematic review and meta-analysis.
    Kim YJ; Lee SG; Lee JS; Choi YJ; Son CG
    J Psychosom Res; 2024 Feb; 177():111589. PubMed ID: 38199049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT; Hien NM; Dung NT; Quang DM; Vinh NT; Tu TT; Chi TK; Phuong LB; Nhan NT
    Med Arch; 2024; 78(2):105-111. PubMed ID: 38566874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study].
    Henriksen M; Høivik ML; Jelsness-Jørgensen LP; Moum B;
    J Crohns Colitis; 2018 Mar; 12(4):389-393. PubMed ID: 29186372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Fairbrass KM; Costantino SJ; Gracie DJ; Ford AC
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1053-1062. PubMed ID: 33010814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life.
    Ozer M; Bengi G; Colak R; Cengiz O; Akpinar H
    Medicine (Baltimore); 2020 May; 99(19):e20067. PubMed ID: 32384473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of functional dyspepsia-like symptoms in ulcerative colitis patients in clinical remission and overlap with irritable bowel syndrome-like symptoms.
    Kotani S; Fukuba N; Kawashima K; Mishima Y; Sonoyama H; Okimoto E; Tada Y; Oka A; Tamagawa Y; Oshima N; Mishiro T; Tobita H; Shibagaki K; Moriyama I; Ishimura N; Kushiyama Y; Fujishiro H; Ishihara S
    Scand J Gastroenterol; 2020 May; 55(5):560-564. PubMed ID: 32412797
    [No Abstract]   [Full Text] [Related]  

  • 20. Cognitive dysfunction in ulcerative colitis patients in remission and its comparison with patients with irritable bowel syndrome and healthy controls.
    Sharma N; Dhiman S; Bodh V; Sharma D; Sharma R; Sharma S; Sharma B
    Indian J Gastroenterol; 2021 Apr; 40(2):169-175. PubMed ID: 33417176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.